ODN 1826 sodium (Synonyms: CpG 1826 sodium) |
| Catalog No.GC26414 |
ODN 1826 sodium is a specific agonist of TLR9.
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
ODN 1826 sodium is a specific agonist of TLR9. It is commonly used in the research of immune regulation and vaccine adjuvants, and can also be used in the study of atherosclerosis[1][2].
ODN 1826 (1μg/mL, 24h) significantly increased the production of NO and iNOS in RAW 264.7 macrophages compared to the negative control[3]. ODN 1826 (3μM, 48h) can increase the cell viability of RAW 264.7 cells even after γ-irradiation. Additionally, ODN 1826 (3μM, 16h) can protect mouse splenocytes from apoptosis induced by γ-irradiation[4].
ODN 1826 (3mg/kg/d, 9 days, i.p.) significantly inhibited tumor growth (up to 40%) compared with animals treated with control ODN or saline in the pancreatic adenocarcinoma mouse model[5]. ODN 1826 (0.05mg; days 1, 3, 5, 8, 10, and 12; i.p.) significantly delayed tumor growth, decreased tumor weight, and increased apoptosis of tumor cells in the Lewis lung cancer mouse model[6].
References:
[1] Zhang X, Gao M, Ha T, et al. The toll-like receptor 9 agonist, CpG-oligodeoxynucleotide 1826, ameliorates cardiac dysfunction after trauma-hemorrhage. Shock. 2012;38(2):146-152.
[2] Krogmann AO, Lüsebrink E, Steinmetz M, et al. Proinflammatory Stimulation of Toll-Like Receptor 9 with High Dose CpG ODN 1826 Impairs Endothelial Regeneration and Promotes Atherosclerosis in Mice. PLoS One. 2016;11(1):e0146326.
[3] Utaisincharoen P, Anuntagool N, Chaisuriya P, et al. CpG ODN activates NO and iNOS production in mouse macrophage cell line (RAW 264.7). Clin Exp Immunol. 2002;128(3):467-473.
[4] Sohn WJ, Lee KW, Choi SY, et al. CpG-oligodeoxynucleotide protects immune cells from gamma-irradiation-induced cell death. Mol Immunol. 2006;43(8):1163-1171.
[5] Tepel J, Dagvadorj O, Kapischke M, et al. Significant growth inhibition of orthotopic pancreatic ductal adenocarcinoma by CpG oligonucleotides in immunodeficient mice. Int J Colorectal Dis. 2006;21(4):365-372.
[6] Yuan S, Qiao T, Chen W. CpG oligodeoxynucleotide 1826 enhances the Lewis lung cancer response to radiotherapy in murine tumor. Cancer Biother Radiopharm. 2011;26(2):203-208.
| Cell experiment [1]: | |
|
Cell lines |
Mouse macrophage cell line RAW 264.7 |
|
Preparation Method |
RAW 264.7 macrophages (1×106 cells/well) were incubated with different concentrations of ODN 1826 or ODN 1982 (negative control) for 24h. |
|
Reaction Conditions |
1μg/mL, 24h |
|
Applications |
ODN 1826 significantly increased the production of NO and iNOS in RAW 264.7 macrophages compared to the negative control. |
| Animal experiment [2]: | |
|
Animal models |
Pancreatic adenocarcinoma mouse model |
|
Preparation Method |
For orthotopic injection, PancTuI cells were trypsinized, washed twice in PBS, resuspended in serum-free RPMI 1640 at a concentration of 107 cells/ml and stored on ice. The viability of the cells was proven by a trypan blue dye exclusion test. General anaesthesia was induced using fentanyl (0.05mg/kg), midazolam (1mg) and medetomidin (0.5mg/kg). A median laparotomy was performed and the pancreas was identified. Thirty microliters of the tumour cell suspension was injected into the corpus of the pancreas. The abdominal wall was closed using Vicryl 6/0. The recovery was carefully supervised with red light rewarming and volume substitution. Seven days after tumour cell injection was performed as described above, mice were randomly assigned either to one of the different treatment groups or to the control group and received a daily intraperitoneal (i.p.) injection of ODN 1826 or ODN 1982 (control ODN) (3mg/kg in 250μL of 0.9% saline) or placebo (250μL of 0.9% saline) over 3 days. Within 21 days, this procedure was repeated three times at intervals of 3 days each (t1-3 q3t). Twenty-eight days after inoculation, animals were sacrificed by carbon dioxide intoxication and the tumour in the pancreas was removed and weighed. Length, width and height were measured and the tumour volume was calculated using the formula recommended in a meta-analysis by Tomayko and Reynolds. |
|
Dosage form |
3mg/kg/d, 9 days, i.p. |
|
Applications |
ODN 1826 significantly inhibited tumor growth (up to 40%) compared with animals treated with control ODN or saline. |
|
References: |
|
| Cas No. | SDF | ||
| Synonyms | CpG 1826 sodium | ||
| Formula | M.Wt | 6804 | |
| Solubility | Storage | -20°C, sealed storage, away from moisture | |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 0.147 mL | 0.7349 mL | 1.4697 mL |
| 5 mM | 0.0294 mL | 0.147 mL | 0.2939 mL |
| 10 mM | 0.0147 mL | 0.0735 mL | 0.147 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *